News stories about SAGE Therapeutics (NASDAQ:SAGE) have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.9039647961849 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Stephen Kanes Sells 44,000 Shares of SAGE Therapeutics Inc (SAGE) Stock (americanbankingnews.com)
- Dorfman colm: Wall Street analysts’ favorites fizzled in 2017 (pilotonline.com)
- Bloomberg Markets: Sage Battling Depression, Powerful Culture (bloomberg.com)
- Sage Therapeutics, Inc., (NASDAQ: SAGE) – Investor’s Roundup (Volatility Analysis) – Stock Watch (stocksnewstimes.com)
- SAGE Therapeutics (SAGE) Given “Buy” Rating at JPMorgan Chase & Co. (americanbankingnews.com)
SAGE Therapeutics (NASDAQ:SAGE) traded up $1.26 during trading on Friday, hitting $175.86. The stock had a trading volume of 322,600 shares, compared to its average volume of 1,070,000. The firm has a market cap of $7,220.00, a price-to-earnings ratio of -25.60 and a beta of 3.05. SAGE Therapeutics has a 52 week low of $44.55 and a 52 week high of $180.83.
SAGE has been the subject of a number of research reports. Royal Bank of Canada lifted their price objective on SAGE Therapeutics from $117.00 to $120.00 in a research report on Thursday, November 2nd. Leerink Swann lifted their price objective on SAGE Therapeutics from $123.00 to $246.00 in a research report on Thursday, December 7th. Needham & Company LLC lifted their price objective on SAGE Therapeutics from $86.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Chardan Capital upgraded SAGE Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $140.00 in a research report on Friday, November 10th. Finally, Raymond James Financial lifted their price objective on SAGE Therapeutics to $109.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $171.21.
In other news, insider Stephen Kanes sold 44,000 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total transaction of $7,795,920.00. Following the completion of the transaction, the insider now directly owns 46,348 shares in the company, valued at approximately $8,211,938.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Albert Robichaud sold 60,000 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $159.43, for a total value of $9,565,800.00. Following the transaction, the insider now owns 152,759 shares of the company’s stock, valued at $24,354,367.37. The disclosure for this sale can be found here. Insiders have sold a total of 314,247 shares of company stock valued at $50,465,110 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.